06
Oct
2009
GlobeImmune (Louisville, CO) a clinical-stage company focused on developing targeted immunogens for the treatment of cancer and infectious diseases, has had an abstract (“GI-5005 Therapeutic Vaccine Plus PEG-IFN/Ribavirin Improves End of Treatment Response at 48 Weeks Versus PEG-IFN/Ribavirin in Naïve Genotype 1 Chronic HCV Patients”) for their investigational hepatitis C virus product candidate accepted for [...]
21
Sep
2009
Tape-Delay from the RMLSIC | Part Deux
Posted in CO Private: ApopLogic, CO Private: BioAmps, CO Private: GlobeImmune, CO Private: InViragen, CO Private: miRagen, CO Private: Myocept, CO Private: Western, MT Private: LigoCyte
Continuing here with Part Deux of the Rocky Mountain Life Science Investor Conference presenting companies. Yesterday CLSDF posted the Diagnostic oriented entities, today we feature the biopharma folks. ApopLogic – Aurora, CO-based AL is a biopharmaceutical company focused on the discovery, and development of therapeutic products that target apoptotic cell death pathways found in cancers, [...]
26
Jun
2008
Congratulations to GlobeImmune for being named to Fierce Biotech’s 2008 Fierce 15 List (click HERE for a link to see the other 15 companies)! What makes it Fierce: GlobeImmune’s third round of financing last fall was its biggest, $41.2M, bringing its total venture haul to north of $88M. Wexford capital led the round and Celgene, [...]
25
Mar
2008
It’s a GlobeImmune kind of day…How exciting to see Dr. Freytag join the GI Board of Directors. Dr. Freytag was President, Chief Executive Officer and Chairman of the Board of Aspreva Pharmaceuticals Company from July 2007 through December 2007 when Aspreva was acquired by Galenica for approximately $915 million. He held the same positions with [...]
25
Mar
2008
GlobeImmune initiated a Phase IIa trial to evaluate their GI-4000 Tarmogen® for the treatment of non-small cell lung cancer (NSCLC) patients with tumors having mutations in the ras gene. NSCLC patients with tumors positive for mutated ras may have a worse survival compared to patients with other NSCLC types and therefore these patients may not [...]
01
Feb
2008
And the CLSDF Readers Have Spoken!
Posted in CO Private: ARCA Discovery, CO Private: GlobeImmune, CO Private: ValveXchange, My Rants
The winner of the CLSDF Reader’s Choice Company of the Year, 2007 goes to… GlobeImmune, Inc., who took home a commanding 43% of the vote. ARCA Discovery and ValveXchange came in tied for second place. Congratulations to President and CEO Tim Rodell, MD and the other 60+ folks in Louisville who are doing outstanding work. [...]
12
Nov
2007
GlobeImmune (Louisville) announced encouraging results from the higher dose cohorts of the randomized, placebo-controlled Phase Ib trial evaluating safety, immunogenicity and efficacy of GI-5005 in patients with chronic hepatitis C infection. The data yielded a favorable safety profile with the dose escalation to the highest planned dose without dose limiting toxicity; strong trends for a [...]
27
Sep
2007
Celgene Makes Ya Go Hmmm…
Posted in CO Private: GlobeImmune, CO Pub Rel: Celgene, CO Public: Array, CO Public: Pharmion
Just what I think to be an interesting observation…that is how deep New Jersey-based Celgene (NASDAQ: CELG) has penetrated into the Colorado bio-scape. The connection appears to have initiated back in 2001 on a licensing deal with Pharmion (NASDAQ: PHRM) for Thalomid® (BTW…take a listen to Pharmion’s UBS Global Life Sciences Conference presentation from today [...]
26
Sep
2007
GlobeImmune, Inc. closed a $41.2MM Series C financing. The round was led by Wexford Capital, other participants include Celgene (NASDAQ: CELG), Mellon Family Investment Company, Richard King Mellon Foundation, Eminent Venture Capital Corp., Boston Life Science Venture, and WRF Capital. Previous investors who participated in the round include HealthCare Ventures, Morgenthaler Ventures, Sequel Venture Partners, [...]
31
Oct
2006
GlobeImmune has announced positive interim data from their randomized, double-blinded placebo-controlled Phase Ib study of their GI-5005 Tarmogen in patients with hepatitis C virus (HCV). To date GI-5005 is well tolerated with no serious adverse events reported. The preliminary data has demonstrated that the treatment has converted subjects with a weak cellular immune response, typical [...]
09
Jun
2006
GlobeImmune, Inc. announced the initiation of a Phase II clinical trial of GI-4000, for the treatment of early-stage pancreas cancer. GI-4000 is designed to activate the immune system against cancer cells containing a mutated protein called Ras that is found in 80-90% of pancreas tumors. In a recently completed Phase 1 study of end-stage pancreas [...]
15
Dec
2005
Today GlobeImmune finished packing and said good bye to the Fitzsimons Redevelopment Authority. Early pre-clinical success, human Phase I clinical trials, multiple rounds of capital raising and hiring have culminated in the need for additional space that Fitzsimons, in its current state, was unable to provide to the accelerating start-up. Another way to look at [...]
Life Science Deal Flow PARTNERS
-
